Zenas BioPharma, Inc. (ZBIO)
Nasdaq: ZBIO · Pharmaceutical Preparations · Waltham, MA · filing with the SEC since 2022
Who owns Zenas BioPharma, Inc.
As filed with the SECHolders of 5% or more
6
Fmr LLC holds 14.3% of COMMON STOCK, as its SCHEDULE 13G/A filed Feb 5, 2026 says.
Directors and officers
15
report now, of 17 people on the record since 2024. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 6 named at left.
Holders of 5% or moreshare of the class, as filed
Fmr LLC
SCHEDULE 13G/A · filed Feb 5, 2026 · COMMON STOCK · 11% in Sep 8, 2025
InnoCare Pharma Inc.
SCHEDULE 13G/A · filed Sep 8, 2026 · Common Stock, par value $0.0001 per share · 9.4% in Oct 15, 2025
Wellington Management Group LLP
SCHEDULE 13G · filed Sep 8, 2026 · Common Stock
SR One Capital Management, LLC
SCHEDULE 13D/A · filed Aug 17, 2026 · Common stock, par value $0.0001 per share · 9.4% in Oct 14, 2025
Moulder Leon O Jr
SCHEDULE 13D · filed May 5, 2026 · Common Stock, $0.0001 par value per share · 4.79% in Apr 2, 2026
Blackrock, Inc.
SCHEDULE 13G · filed Oct 27, 2026 · Common Stock
Enavate Sciences GP, LLC
SCHEDULE 13D/A · filed Aug 19, 2026 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 7.3% in Oct 14, 2025
Patrick G. Enright
SCHEDULE 13D/A · filed Oct 14, 2025 · Common Stock, $0.0001 par value per share · reported falling below 5%
Novo Holdings A/S
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, par value $0.0001 · reported falling below 5%, from 5.3% in Apr 1, 2025
What ZBIO reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Zenas BioPharma (HK) Limited
An entity · consolidated entity · owns, named in the 10-K filed Mar 16, 2026
Insider tradesForm 4
0sales
23purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$26.6Mbought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window8 of 23 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Moulder Leon O Jr | Chief Executive Officer | 0 | $0 | 0 | 10 | $6.5M |
| Allen Patricia L | director | 0 | $0 | 0 | 4 | $500,000 |
| Lu Hongbo | director | 0 | $0 | 0 | 4 | $7.2M |
| Enright Patrick G | director | 0 | $0 | 0 | 2 | $2.3M |
| Sr One Capital Management, LLC | 10% owner | 0 | $0 | 0 | 2 | $2.4M |
| Nunn Jason Raleigh | director | 0 | $0 | 0 | 1 | $1.2M |
| Harwin Peter Evan | director | 0 | $0 | 0 | 1 | $6.0M |
| Kiselak Tomas | director | 0 | $0 | 0 | 1 | $3.0M |